Drug Type Small molecule drug |
Synonyms Remofuscin, Soraprazan, BY 359 + [2] |
Target |
Action blockers |
Mechanism H+/K+ ATPase blockers(Potassium-transporting ATPase blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H25N3O3 |
InChIKeyPWILYDZRJORZDR-MISYRCLQSA-N |
CAS Registry261944-46-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stargardt Disease | Phase 2 | Netherlands | - | 09 May 2019 |
Gastroesophageal Reflux | Phase 2 | Germany | - | |
Gastroesophageal Reflux | Phase 2 | - | - |
Not Applicable | - | - | vqbpmpgijc(zywtbbnfty): RR = 1.17 (95% CI, 1.11 - 1.22) | - | 18 May 2024 | ||
Conventional PPI-based triple therapy | |||||||
Not Applicable | - | bdzvpvvygf(nmiflgpsxb) = hecbgevazw xtrunbyjpk (bzxvpfiyvx ) View more | - | 05 Oct 2023 | |||
Placebo | bdzvpvvygf(nmiflgpsxb) = scktgwqgml xtrunbyjpk (bzxvpfiyvx ) View more |